450
Participants
Start Date
June 30, 2024
Primary Completion Date
December 15, 2026
Study Completion Date
December 15, 2028
ctDNA monitoring
For each patient included, a ctDNA detection assay will be performed in blood samples every 3 months, while extra-plasma will be banked. ctDNA results will be available with a turnaround time of less than 3 weeks. When negative, ctDNA detection results will not be disclosed to patients nor clinicians.
68Ga-FAPI-46-PET-CT
). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.
Institut Paoli-Calmettes, Marseille
CHU Nîmes, Nîmes
ONCOPOLE Claudius Regaud, Toulouse
Institut Bergonié, Bordeaux
Institut du cancer de Montpellier, Montpellier
Centre Eugène Marquis, Rennes
Institut de cancérologie de Lorraine, Vandœuvre-lès-Nancy
Centre Jean Perrin, Clermont-Ferrand
Centre Leon Bérard, Lyon
Hôpital Saint-Louis, Paris
Hôpital Tenon, Paris
Sainte-Catherine Institut du Caner Avignon-Provence, Avignon
Institut Curie, Saint-Cloud
National Research Agency, France
OTHER
Roche Pharma AG
INDUSTRY
Institut Curie
OTHER